They tested the propensity of the COVID-19 virus’s spike protein, which it uses to enter cells, to bind to the human type of ACE2 as well as to many different animal versions of ACE2, and found that the novel coronavirus most powerfully binds with human ACE2, and with variously lesser degrees of effectiveness with animal versions of the receptor.
